福安药业：注射用硫酸艾沙康唑取得药品注册证书

Core Viewpoint - Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Hubei Renmin Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for the injectable drug, Isavuconazole Sulfate, which is indicated for the treatment of invasive aspergillosis and mucormycosis in adult patients [1] Group 1 - The drug Isavuconazole Sulfate is specifically designed for treating serious fungal infections [1] - The approval of this drug expands the company's product portfolio in the antifungal treatment segment [1] - This development may enhance the company's market position in the pharmaceutical industry, particularly in the area of critical care medications [1]